Director/PDMR Shareholding

RNS Number : 2522I

Avacta Group PLC

10 June 2011

 



Press release

10 June 2011

Avacta Group plc

("Avacta" or "the Group")

Director/PDMR Shareholding

The Company announces that earlier today Alastair Smith, Chief Executive Officer, transferred 1,952,250 ordinary shares of 0.1p each ("Ordinary Shares") to his Self Invested Pension Plan ("SIPP").  As a result of this transaction his beneficial holding remains unchanged at 51,728,296Ordinary Shares, which represents approximately 3.10 % per cent. of the current issued share capital of the Company.

-Ends-

For further information please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer	Tel:  [phone] www.avacta.com
Broker XCAP Securities plc John Grant/Karen Kelly/David Newton	Tel:  [phone] www.xcapgroup.com
Nominated Adviser Grant Thornton Corporate Finance Philip Secrett/Colin Aaronson	Tel:  [phone] www.grantthornton.co.uk
Media Enquiries Abchurch Communications Sarah Hollins/Adam Michael/Simone Elviss/ Oliver Hibberd	Tel: [phone] www.abchurch-group.com

Notes to Editors:

Avacta Group plc, a world leading, UK-based healthcare equipment and instrumentation business, provides innovative, high value proprietary technologies and services to the life sciences/healthcare sector through two operating divisions:

Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a $200bn revenues market by 2013 and the fastest growing part of the pharmaceutical industry. The Group's technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Group's lead analytical instrument, Optim, is distributed through Pall Corporation in the US, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.

Avacta Animal Health provides diagnostic products and services for the $1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information, through point of care diagnostics, reagents and testing kits and laboratory based testing. Avacta's AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta's world leading allergy testing brand Sensitest®.Avacta is currently developing further assays for the AX-1 system to diagnose other diseases in companion animals. Longer term this technology will be transferred into the human clinical diagnostics market.

Avacta joined AIM in August 2006 and is based in Wetherby and York, England.

 

END

 

 

RDSDKKDPDBKDKAD